Spots Global Cancer Trial Database for kras mutation
Every month we try and update this database with for kras mutation cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Phase II Study of VS-6063 in Patients With KRAS Mutant Non-Small Cell Lung Cancer | NCT01951690 | Non Small Cell ... Lung Cancer | defactinib (VS-... | 18 Years - | Verastem, Inc. | |
| Pemetrexed and Gemcitabine for Treatment Resistant Patients With Metastatic Colorectal Cancer and KRAS Mutations | NCT01109615 | Metastatic Colo... | Pemetrexed Gemcitabine | 18 Years - | Vejle Hospital | |
| Sorafenib in Combination With Irinotecan in Metastatic Colorectal Cancer Patients With KRAS Mutated Tumors | NCT01715441 | Metastatic Colo... | Sorafenib and i... Sorafenib monot... Irinotecan mono... | 18 Years - | Institut du Cancer de Montpellier - Val d'Aurelle | |
| Study of Onvansertib in Combination With FOLFIRI and Bevacizumab Versus FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer in Participants With a Kirsten Rat Sarcoma Virus Gene (KRAS) or Neuroblastoma-RAS (NRAS) Mutation | NCT05593328 | Colorectal Canc... Metastatic Colo... | Onvansertib FOLFIRI Bevacizumab | 18 Years - | Cardiff Oncology | |
| MK-2206 and AZD6244 in Patients With Advanced Colorectal Carcinoma | NCT01333475 | Colorectal Neop... | MK-2206 + AZD62... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Study of Avutometinib (VS-6766) +Defactinib With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer | NCT05669482 | KRAS Activating... Metastatic Canc... Pancreas Cancer Neoplasms Pancr... Malignant Neopl... | avutometinib (V... | 18 Years - | Verastem, Inc. | |
| Combination Chemotherapy Plus Panitumumab or Bevacizumab for Inoperable Cholangiocarcinoma Without KRAS Mutations | NCT01206049 | Cholangiocarcin... | Gemcitabine Oxaliplatin Capecitabine Panitumumab Bevacizumab | 18 Years - | Vejle Hospital | |
| A Study of RNA Tumor Vaccine in Patients With Advanced Solid Tumors | NCT05202561 | Advanced Solid ... | RNA tumor vacci... RNA tumor vacci... | 18 Years - | First Affiliated Hospital Bengbu Medical College | |
| AZD6244 in Combination With Docetaxel Versus Docetaxel Alone in KRAS Mutation Positive NSCLC Patients | NCT00890825 | Non Small Cell ... | AZD6244 docetaxel Placebo | 18 Years - 130 Years | AstraZeneca | |
| Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer | NCT01395758 | Metastatic Non-... | ARQ 197 plus er... Pemetrexed, doc... | 18 Years - | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | |
| Study of Onvansertib in Combination With FOLFIRI and Bevacizumab Versus FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer in Participants With a Kirsten Rat Sarcoma Virus Gene (KRAS) or Neuroblastoma-RAS (NRAS) Mutation | NCT05593328 | Colorectal Canc... Metastatic Colo... | Onvansertib FOLFIRI Bevacizumab | 18 Years - | Cardiff Oncology | |
| Neoadjuvant Treatment of Colon Cancer | NCT01108107 | Colon Cancer | Oxaliplatin Capecitabine Oxaliplatin Capecitabine Panitumumab | 18 Years - | Vejle Hospital | |
| Combination Chemotherapy Plus Panitumumab or Bevacizumab for Inoperable Cholangiocarcinoma Without KRAS Mutations | NCT01206049 | Cholangiocarcin... | Gemcitabine Oxaliplatin Capecitabine Panitumumab Bevacizumab | 18 Years - | Vejle Hospital | |
| MK-2206 and AZD6244 in Patients With Advanced Colorectal Carcinoma | NCT01333475 | Colorectal Neop... | MK-2206 + AZD62... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Technical Optimization of Detection of KRAS, BRAF and NRAS Mutations on Tumor DNA Circulating in Metastatic Colorectal Cancer | NCT02827565 | Metastatic Colo... | KRAS, NRAS et B... | 18 Years - | Institut de Cancérologie de Lorraine | |
| Real-Time Monitoring of Symptoms in Lung Cancer Patients Receiving Oral Targeted Therapies | NCT05370469 | Lung Cancer EGFR Gene Mutat... EGFR ALK Gene Mutati... RET Gene Mutati... MET Gene Mutati... KRAS Mutation-R... BRAF ROS1 Gene Mutat... | Sensus Smartwat... RX Cap Fitbit Sense Surveys | 18 Years - | University of Virginia | |
| A Phase I/IB Trial of MEK162 in Combination With Erlotinib in NSCLC Harboring KRAS or EGFR Mutation | NCT01859026 | Lung Cancer Non-Small Cell ... | MEK162 Erlotinib | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Assessment of Clinical Practice Administration of Chemotherapy and Anti-angiogenic Agent (Bevacizumab) in Colorectal Cancer | NCT01811108 | Metastatic Colo... | 18 Years - | Hellenic Oncology Research Group | ||
| KRAS Mutation and Incidence of the Colorectal Carcinoma in Martinique Between 2007 and 2009 | NCT01151007 | Colorectal Carc... | 18 Years - | University Hospital Center of Martinique | ||
| Temsirolimus and Irinotecan for Treatment Resistant Patients With Metastatic Colorectal Cancer and KRAS Mutations | NCT00827684 | Metastatic Colo... | Irinotecan Temsirolimus | 18 Years - 70 Years | Vejle Hospital | |
| Efficacy and Safety Study of Imprime PGG With Cetuximab in Subjects With Stage IV KRAS-Mutated Colorectal Cancer | NCT00912327 | Colorectal Canc... | Imprime PGG | 18 Years - | HiberCell, Inc. | |
| Study of RXDX-105, Potent RET Inhibitor in Patients With Advanced Lung Cancer and Other Solid Tumors | NCT01877811 | Solid Tumors | RXDX-105 | 18 Years - | Hoffmann-La Roche | |
| Technical Optimization of Detection of KRAS, BRAF and NRAS Mutations on Tumor DNA Circulating in Metastatic Colorectal Cancer | NCT02827565 | Metastatic Colo... | KRAS, NRAS et B... | 18 Years - | Institut de Cancérologie de Lorraine | |
| A Study of YL-17231 in Patients With Advanced Solid Tumors | NCT06078800 | Advanced Solid ... | YL-17231 | 18 Years - 75 Years | Shanghai YingLi Pharmaceutical Co. Ltd. | |
| SHP2 Inhibitor BBP-398 in Combination With Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer With a KRAS Mutation | NCT05375084 | Non Small Cell ... Solid Tumor | BBP-398 with ni... | 18 Years - | Navire Pharma Inc., a BridgeBio company |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
